ADICET BIO INC (ACET)

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates

Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024

Adicet Bio to Participate in Upcoming Investor Conferences

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio to Present at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference

Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors

ACET Stock Earnings: Adicet Bio Beats EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Adicet Bio (NASDAQ:ACET) just reported results for the second quarter of 2024.A...

ACET Stock Earnings: Adicet Bio Beats EPS for Q2 2024

ACET stock results show that Adicet Bio beat analyst estimates for earnings per share the second quarter of 2024.

Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates

Adicet Bio to Participate in Upcoming Investor Conferences

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma

Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024

These are the biotech stocks under $10 that are attractively valued and have potential catalysts in the form of positive clinical trials news

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference

ACET Stock Earnings: Adicet Bio Beats EPS for Q1 2024

ACET stock results show that Adicet Bio beat analyst estimates for earnings per share the first quarter of 2024.

ACET Stock Earnings: Adicet Bio Beats EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Adicet Bio (NASDAQ:ACET) just reported results for the first quarter of 2024.Ad...

Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates

Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress

Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting